Holen Sie sich die Stockscreener-App
36.99
0.78%
-0.29
Schlusskurs vom Vortag:
$37.28
Offen:
$37.01
24-Stunden-Volumen:
677.50K
Relative Volume:
0.49
Marktkapitalisierung:
$3.56B
Einnahmen:
$225.27M
Nettoeinkommen (Verlust:
$-140.06M
KGV:
-23.16
EPS:
-1.5974
Netto-Cashflow:
$-87.93M
1W Leistung:
-1.75%
1M Leistung:
+34.02%
6M Leistung:
-1.04%
1J Leistung:
+62.24%
1-Tages-Spanne:
$35.92
$37.42
1-Wochen-Bereich:
$35.92
$40.58
52-Wochen-Spanne:
$21.33
$40.58
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
36.99 | 3.56B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-09-04 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Ideaya Biosciences chief accounting officer sells $382,130 in stock - Investing.com
Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com - Investing.com Nigeria
Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com - Investing.com Nigeria
IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan
Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer - ad-hoc-news.de
IDEAYA Biosciences (IDYA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary - Quartr
How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing - Stock Traders Daily
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - AOL.com
Form 144 IDEAYA Biosciences For: 7 July By Investing.com - Investing.com South Africa
[144] IDEAYA Biosciences, Inc. SEC Filing - Stock Titan
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63 - Moomoo
IDYA Maintains Outperform Rating by RBC Capital -- Price Target Lowered to $48 - GuruFocus
RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating - Moomoo
Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com - Investing.com South Africa
Ideaya Biosciences stock hits 52-week high at $39.28 - Investing.com
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBITDA forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc. Actuals & Estimates (SWB:30J) - TradingView
30J Forecast — Price Target — Prediction for 2027 - TradingView
(IDYA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
IDEAYA Biosciences, Inc. Actuals & Estimates (DUS:30J) - TradingView
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Biosciences, Inc. Actuals & Estimates (NASDAQ:IDYA) - TradingView
IDEAYA lures 4 new hires with 98,000 stock options - Stock Titan
IDYA Forecast — Price Target — Prediction for 2027 - TradingView
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes - TipRanks
Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair - Stock Titan
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant - Stock Titan
IDEAYA Biosciences (IDYA) director receives stock options on 20,000 shares - Stock Titan
IDEAYA (IDYA) director receives grant of 20,000 stock options - Stock Titan
IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57 - Stock Titan
IDEAYA (IDYA) director Scott Morrison receives grant of 20,000 stock options - Stock Titan
IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares - Stock Titan
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):